CBIO: CR-001 aims to become a next-generation IO backbone, with phase III starts targeted for early 2028Quartr·Nov 10, 2026 at 08:18 PMCBIO-3.41%GLYC0.00%
Jiangsu Recbio Expects REC603 HPV Vaccine Launch in 2029-2030 as Clinical Data Collection Takes LongerPUBT·Nov 9, 2026 at 08:50 AM021790.00%
Jiangsu Recbio Announces Board-Level Resignation and New Authorised RepresentativeTip Ranks·Aug 25, 2026 at 09:41 AM021790.00%
Jiangsu Recbio files board, committee member roster for disclosure dutiesPUBT·Aug 25, 2026 at 09:12 AM021790.00%
Jiangsu Recbio Clarifies Board Composition and Committee LeadershipTip Ranks·Aug 19, 2026 at 02:38 PM021790.00%
Jiangsu Recbio files board, board committee member list with disclosure rolesPUBT·Aug 19, 2026 at 02:11 PM021790.00%
Jiangsu Recbio Formalizes H Share Full Circulation with Amended ArticlesTip Ranks·Aug 17, 2026 at 02:08 PM021790.00%
Jiangsu Recbio schedules board meeting to review interim results, consider dividendPUBT·Aug 7, 2026 at 12:59 PM021790.00%
Recbio Reports Shingles Vaccine Milestone and Delay in HPV FilingTip Ranks·Jul 23, 2026 at 10:40 AM021790.00%
Jiangsu Recbio says NMPA accepts filing for REC610 shingles vaccine approvalPUBT·Jul 23, 2026 at 10:25 AM021790.00%
Beijing Ubox Online files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jul 21, 2026 at 10:00 AM021790.00%02429-0.75%
RECBIO H shares full circulation has been filed with the China Securities Regulatory Commission, involving a conversion of 24% equity in H sharesAASTOCKS·Feb 2, 2026 at 02:57 AM021790.00%
Recbio Gains CSRC Green Light for Full Circulation of 142 Million Domestic Shares as H SharesTip Ranks·Jan 30, 2026 at 03:09 PM021790.00%